ETF Holdings Breakdown of PHAT

News associated with PHAT

Wells Fargo & Company MN Grows Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Wells Fargo & Company MN boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) by 41.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 25,516 shares of the company’s stock after purchasing an additional 7,462 shares during the quarter. Wells Fargo & Company MN’s holdings in Phathom Pharmaceuticals were worth $207,000 […] - 2025-05-09 07:16:49

Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $21.83

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating […] - 2025-05-02 05:26:49

Raymond James Financial Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Raymond James Financial Inc. bought a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 455,837 shares of the company’s stock, valued at approximately $3,701,000. Other large investors also […] - 2025-04-28 08:05:16

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns “Buy” Rating from Needham & Company LLC

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $28.00 price target on the stock. Several other analysts have also recently weighed in on the company. […] - 2025-04-23 06:13:04

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Consensus PT from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to […] - 2025-04-09 06:10:49

Virtu Financial LLC Acquires New Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Virtu Financial LLC acquired a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 13,424 shares of the company’s stock, valued at approximately $109,000. Other institutional investors and hedge funds have also modified their holdings of the company. Intech Investment Management LLC acquired […] - 2025-03-31 07:45:00

Raymond James Financial Inc. Purchases Shares of 455,837 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 455,837 shares of the company’s stock, valued at approximately $3,701,000. Several other institutional investors […] - 2025-03-28 08:04:52

Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group

Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the stock. A number of other research firms have also commented on PHAT. HC Wainwright reissued a […] - 2025-03-11 06:40:47

Los Angeles Capital Management LLC Takes $171,000 Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Los Angeles Capital Management LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 21,070 shares of the company’s stock, valued at approximately $171,000. Other hedge funds and other institutional investors […] - 2025-03-06 10:56:59

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Cantor Fitzgerald

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. A number of other analysts have also weighed in on PHAT. HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares […] - 2025-02-27 06:14:49

Phathom Pharmaceuticals (NASDAQ:PHAT) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating and a $23.00 target price on the stock. A number of other analysts have also commented on the stock. Needham & Company LLC reiterated a “buy” […] - 2025-02-17 06:59:03

PHAT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	33,423	USD 76,539 -4.8%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	34,018	USD 77,901
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	34,018	USD 77,901 -4.8%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	412	USD 943 -4.9%
Total =		101,871	USD 233,284

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer